Purpose:To estimate the curative effects and side effects obtained from high-dose epirubicin (EPI) combination therapy in the treatment of advanced chest malignant tumors. Methods:Forty-eight cases with advanced chest malignant tumor(32 cases with non-small-cell lung cancer; eleven cases with breast cancer and five cases with mediastinal malignant lymphomas) were treated with the combination therapy of high-dose EPI. Results:The response rate in non-small-cell lung cancer was 56.3%, in breast cancer was 72.7%, in mediastinal malignant lymphomas was 100%. The most frequent toxicities were neutropenia.Conclusions:The combined chemotherapy of high-does EPI is an effective and safe treatment in advanced chest malignant tumor.